Showing 2441-2450 of 5623 results for "".
- Nicox’s Completes Pre-Defined Enrollment of NCX 4251 Mississippi Phase 2b Blepharitis Trialhttps://modernod.com/news/nicoxs-completes-pre-defined-enrollment-of-ncx-4251-mississippi-phase-2b-blepharitis-trial/2479250/Nicox announced that more than 200 patients, the pre-defined target, have been randomized in the NCX 4251 Mississippi phase 2b blepharitis clinical trial. Topline results are expected to be announced during September 2021. “Blepharitis is a highly prevalent eye condition with frequent exac
- Samsara Vision: Patients Blinded by Macular Degeneration May Benefit From Implant Technologyhttps://modernod.com/news/samsara-vision-reports-that-patients-blinded-by-macular-degeneration-benefit-from-milestone-in-implant-technology/2479242/Samsara Vision announced the first successful clinical cases in Europe using their smaller-incision new-generation implantable miniature telescope (SING IMT) for people living with late-stage age-related macular degeneration (AMD). The SING IMT, performed with the TSert delivery system, was succe
- The Children’s Eye Foundation of AAPOS Debuts “THE CURIOUS EYE” Interactive Storybookhttps://modernod.com/news/the-childrens-eye-foundation-of-aapos-debuts-the-curious-eye-interactive-storybook/2479230/The Children’s Eye Foundation of AAPOS unveiled the world’s first interactive children’s book to help screen for color vision deficiency (CVD), commonly known as color blindness. The foundation has posted a free digital version of THE CURIOUS EYE at
- Essilor Receives FDA Breakthrough Device Designation for Essilor Stellest Spectacle Lenshttps://modernod.com/news/essilor-receives-fda-breakthrough-device-designation-for-essilor-stellest-specticle-lens/2479220/Essilor announced that the FDA has granted Breakthrough Device designation to its Essilor Stellest spectacle lens, the company’s new generation lens developed to correct myopia and slow down the progression of myopia in children. The designation of the Essilor’s Stellest spectacle lens as
- Prevent Blindness Declares Second Annual Inherited Retinal Disease (IRD) Genetic Testing Week as May 16-22https://modernod.com/news/prevent-blindness-declares-second-annual-inherited-retinal-disease-ird-genetic-testing-week-as-may-16-22/2479209/Prevent Blindness has declared the second annual “Inherited Retinal Disease (IRD) Genetic Testing Week” as May 16-22, 2021. As part of this initiative, Prevent Blindness will be posting a series of educational graphics on its social media channels, including Facebook, Twitter, and Instagram.
- NUST MISIS Scientists Say They Developed a Safe Drug to Treat Eye Inflammationhttps://modernod.com/news/nust-misis-scientists-say-they-developed-a-safe-drug-to-treat-eye-inflammation/2479203/A Russian-American research team from The National University of Science and Technology MISIS has presented a new therapeutic method using nanoparticles of an antioxidant enzyme, developed specifically for the eyes. It relieves inflammation and repairs tissue without causing side effects: irritat
- Lumenis Named “Best Overall Medical Device Company” in 2021 MedTech Breakthrough Awardshttps://modernod.com/news/lumenis-named-best-overall-medical-device-company-in-2021-medtech-breakthrough-awards/2479201/Lumenis announced that it has been selected as the “Best Overall Medical Device Company” in the MedTech Breakthrough Awards. MedTech Breakthrough is an independent market intelligence organization that honors excellence and recognizes the top companies, technologies and products in the global he
- Mount Sinai Ophthalmologists Develop New Technique to Assess Progression of Sickle Cell Retinopathyhttps://modernod.com/news/mount-sinai-ophthalmologists-develop-new-technique-to-assess-progression-of-sickle-cell-retinopathy/2479189/Ophthalmologists at New York Eye and Ear Infirmary of Mount Sinai have created a new technique to evaluate patients with sickle cell retinopathy and assess the disease before it progresses and leads to permanent vision loss. Using optical coherence tomography (OCT) angiography, the resear
- Tarsus Pharmaceuticals Initiates Saturn-2 Phase 3 Trial Evaluating the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitishttps://modernod.com/news/tarsus-pharmaceuticals-initiates-saturn-2-phase-3-trial-evaluating-the-safety-and-efficacy-of-tp-03-for-the-treatment-of-demodex-blepharitis/2479179/Tarsus Pharmaceuticals announced that it has commenced enrollment in Saturn-2, its second pivotal trial evaluating the company’s novel investigational treatment, TP-03, in patients with Demodex blepharitis. Up to 25 million Americans may be affected by Demodex blepharitis, which is caused by an i
- Verana Health: Study Demonstrates Promise of Real-World Data in Ophthalmic Clinical Developmenthttps://modernod.com/news/verana-health-study-demonstrates-promise-of-real-world-data-in-ophthalmic-clinical-development/2479172/Verana Health unveiled research during the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. In a first-of-its kind study, Verana Health demonstrated that it was able to successfully use